WHAT IS CLAIMED IS:

5

10

. 15

20

25

30

- 1. An isolated mammalian polypeptide comprising the sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 21, SEQ ID NO: 23. SEQ ID NO: 25, SEQ ID NO: 27 or SEQ ID NO: 29, or variant polypeptides corresponding to SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 21, SEQ ID NO: 23. SEQ ID NO: 25, SEQ ID NO: 27 or SEQ ID NO: 29, in which one or more amino acids are replaced, deleted, inserted and/or added.
- 2. An isolated mammalian polypeptide comprising the sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 24. SEQ ID NO: 26, SEQ ID NO: 28 or SEQ ID NO: 30, or variant polypeptides corresponding to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 10 or SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 24. SEQ ID NO: 26, SEQ ID NO: 28 or SEQ ID NO: 30, in which one or more amino acids are replaced, deleted, inserted and/or added.
- 3. An isolated mammalian polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 15 or SEQ ID NO: 19, or variant nucleic acids that encode for variant polypeptides corresponding to SEQ ID NO: 1 SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 13 or SEQ ID NO: 17, in which one or more amino acids are replaced, deleted, inserted and/or added.
 - 4. An isolated mammalian polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 16 or SEQ ID NO: 20, or variant nucleic acids that encode for variant polypeptides corresponding to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 14 or SEQ ID NO: 18, in which one or more amino acids are replaced, deleted, inserted and/or added.
- 5. A pharmaceutical composition comprising one or more mature polypeptides of SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24. SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29 or SEQ ID NO: 30, or variant mature polypeptides corresponding to SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24. SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29 or SEQ ID NO: 30, in which one or more amino acids are replaced, deleted, inserted and/or added, wherein the polypeptide is an active agent in the pharmaceutical composition.

6. A vector comprising the nucleic acid sequence of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 19 or SEQ ID NO: 20, or variant nucleic acids that encode for variant polypeptides corresponding to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 9 or SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 17 or SEQ ID NO: 18, in which one or more amino acids are replaced, deleted, inserted and/or added.

- 7. A pharmaceutical composition comprising one or more polypeptides encoded for by SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 19 or SEQ ID NO: 20, or encoded for by variant nucleic acids that encode for variant polypeptides corresponding to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 9 or SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24. SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29 or SEQ ID NO: 30, in which one or more amino acids are replaced, deleted, inserted and/or added.
- 8. An isolated antibody comprising an antigenic polypeptide that binds to a specific portion of a polypeptide sequence of claim 1 or 2.
 - 9. A kit comprising one or more polypeptides of claim 1 or 2, wherein the kit comprises:
 - a) instructional material for the one or more polypeptides; or
 - b) one or more containers into which the one or more polypeptides are segregated.
 - 10. A method of producing one or more polypeptides, the method comprising:
 - a) culturing transformed cells comprising one or more vectors of claim 6; and
 - b) isolating the one or more polypeptides.
- 11. A method of screening for a compound that binds to a polypeptide, the method comprising:
 - a) contacting one or more test compounds with a polypeptide of claim 1 or 2;
 - b) determining whether a test compound binds to the polypeptide; and
 - c) selecting the test compound that binds to the polypeptide.

25

5

10

15

20

12. A method of screening for a polypeptide that binds to a cell, the method comprising:

- a) contacting a polypeptide of claim 1 or 2 with a cell; and
- b) determining whether the polypeptide binds to the cell.
- 13. The method of claim 12, wherein the cell is a hematopoietic cell.
- 14. The method of claim 12, wherein the cell is a neuronal cell.
- 15. The method of claim 13, wherein the hematopoietic cell is a progenitor or stem cell.
- 16. The polypeptides of claim 1 or 2, wherein the polypeptides are modified.
- 17. The polypeptides of claim 16, wherein the polypeptides are lipid modified.
- 18. The polypeptides of claim 16, wherein the polypeptides are glycosylated.
- 19. The polypeptides of claim 16, wherein the polypeptides are modified by acylation.
- 20. A method of modulating the physiology of a cell type, the method comprising:
 - a) contacting the cell type with a polypeptide of claim 1 or 2; and
 - b) monitoring the cell type for a change in physiology.

21. An isolated mammalian nucleic acid comprising the sequence of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 19 or SEQ ID NO: 20, or variant nucleic acids that encode for variant polypeptides corresponding to SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 21, SEQ ID NO: 23. SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 24. SEQ ID NO: 26, SEQ ID NO: 28 or SEQ ID NO: 30, in which one or more amino acids are replaced, deleted, inserted and/or added.

22. A binding partner comprising:

5

10

15

20

25

a molecule that binds to a polypeptide of claim 1 or 2 with a Kd of approximately $10^{-8} M$ or greater or binds to a nucleic acid of claim 3, 4 or 21 with a Kd of approximately $10^{-8} M$ or greater.

23. An interference molecule comprising:

a RNAi molecule generated to interfere with the protein expression of a polypeptide of claim 1 or 2.

24. An aptamer molecule comprising:

a nucleic acid molecule generated to specifically bind to a portion of a polypeptide of claim 1 or 2.